Imprivata (NYSE: IMPR) and American Software (NASDAQ:AMSWA) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.
This table compares Imprivata and American Software’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Imprivata and American Software, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
American Software has a consensus price target of $14.00, suggesting a potential upside of 14.57%.
Institutional and Insider Ownership
59.3% of Imprivata shares are held by institutional investors. Comparatively, 74.6% of American Software shares are held by institutional investors. 40.2% of Imprivata shares are held by insiders. Comparatively, 13.9% of American Software shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Imprivata and American Software’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|American Software||$106.29 million||3.47||$14.62 million||$0.59||20.71|
American Software has higher revenue and earnings than Imprivata. Imprivata is trading at a lower price-to-earnings ratio than American Software, indicating that it is currently the more affordable of the two stocks.
American Software pays an annual dividend of $0.44 per share and has a dividend yield of 3.6%. Imprivata does not pay a dividend. American Software pays out 74.6% of its earnings in the form of a dividend.
American Software beats Imprivata on 9 of the 11 factors compared between the two stocks.
Imprivata Company Profile
Imprivata, Inc. (Imprivata) is a United States-based healthcare information technology security company. The Company enables healthcare organizations to access, communicate and transact patient information securely. The Company offers Imprivata OneSign, Imprivata Cortext, Imprivata Confirm ID and Imprivata PatientSecure. Imprivata OneSign provides single sign-on, authentication management and virtual desktop roaming, enabling No Click Access to clinical applications and patient information, anytime, anywhere and from any device. Imprivata Cortext enables clinicians to collaborate across care teams and organizations. Imprivata Confirm ID is an identity and two-factor authentication platform for remote access, electronic prescriptions for controlled substances (EPCS), medical device access and other clinical authentication workflows. Imprivata PatientSecure is a patient identification solution that uses palm vein recognition biometrics to identify patients at any point of entry to care.
American Software Company Profile
American Software, Inc. (American Software) develops, markets and supports a portfolio of software and services that delivers enterprise management, supply chain and retail planning solutions to the marketplace. The Company operates through three business segments: Supply Chain Management (SCM), Enterprise Resource Planning (ERP) and Information Technology (IT) Consulting. The SCM segment consists of Logility, Inc. and its subsidiary, Demand Management, Inc. (DMI), both of which provide supply chain and retail planning solutions to trading partners. The ERP segment consist of American Software ERP, which provides business software for manufacturers and distributors, and New Generation Computing, Inc. (NGC), which provides industry-specific business software to both retailers and manufacturers in the apparel, footwear, sewn products and furniture industries. The IT Consulting segment consists of The Proven Method, Inc., an IT staffing and consulting services firm.
Receive News & Ratings for Imprivata Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprivata and related companies with MarketBeat.com's FREE daily email newsletter.